William James Smith

Dr. William James Smith

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2021 in Vaccine
Verified
Journal Article
Closed access
DMDebra McGuinness
Debra McGuinness
RKRobin M. Kaufhold
Robin M. Kaufhold
PMPatrick M. McHugh
Patrick M. McHugh
MWMichael A Winters
Michael A Winters
WSWilliam James Smith
William James Smith
JSJulie M. Skinner
Julie M. Skinner

15 June 2023 in Vaccine
Verified
Journal Article
Closed access
WSWilliam James Smith
William James Smith
RTRachel Thompson
Rachel Thompson
PEPatricia M. Egan
Patricia M. Egan
YZYuhua Zhang
Yuhua Zhang
LILani Indrawati
Lani Indrawati
MWMichael A. Winters
Michael A. Winters

7 June 2022 in Vaccine
Verified
Journal Article
Closed access
WSWilliam James Smith
William James Smith
PAPatrick L. Ahl
Patrick L. Ahl
BWBei Wang
Bei Wang
MHMelissa Hamm
Melissa Hamm
RRRichard R. Rustandi
Richard R. Rustandi
JBJeffrey T. Blue
Jeffrey T. Blue


5 July 2025 in Journal of Pharmaceutical Analysis
Verified
Journal Article
Open access
EPEmory M. Payne
Emory M. Payne
EPErika Patel
Erika Patel
FOFaith O. Osinaga
Faith O. Osinaga
MWMarissa L. Wolfle
Marissa L. Wolfle
TLTian Lu
Tian Lu
WSWilliam James Smith
William James Smith

5 February 2026 in Vaccines
Verified
Journal Article
Open access
PDF file
YJYuhyun Ji
Yuhyun Ji
KBKavitha Bekkari
Kavitha Bekkari
MSMohammed Shardar
Mohammed Shardar
GWGeoffrey A. Walford
Geoffrey A. Walford
SKSamMoon Kim
SamMoon Kim
NSNicole Lea Sullivan
Nicole Lea Sullivan
Background/Objectives: Adjuvants, added to vaccines to enhance immune responses, are central to shaping the magnitude and durability of immunity, yet their precise mechanisms remain incompletely defined. This study evaluated how diverse adjuvant combinations influence HPV vaccine immunogenicity in non-human primates, with a particular focus on impacts on hematopoietic biology—megakaryocytes and platelets—and broader innate and adaptive pathways. Methods: Eight adjuvanted formulations, each incorporating distinct immunomodulatory components and delivery platforms, were compared against an alum-only control in non-human primates. Longitudinal antibody titers (HPV16-specific) were measured up to 54 weeks, and blood transcriptomes were profiled at Day 1 and Day 7 after both prime and boost doses to assess pathway-level enrichment and gene-expression patterns. Results: Several adjuvant combinations significantly increased antibody titers at 54 weeks compared with alum alone. Formulations containing cationic lipid or monophosphoryl lipid A (MPL) were associated with enhanced antibody responses. Early upregulation of immune-related genes across innate and adaptive pathways was also observed, with some combinations (e.g., inclusion of QS21 or ISCOMs) showing similar trends. Distinct group- and time-dependent transcriptional signatures were observed, with higher-responding formulations exhibiting stronger enrichment in pathogen-influenced signaling and cellular/humoral immune programs. Conclusions: Adjuvant selection and formulation strategy substantially modulate vaccine immunogenicity and early transcriptional programs, including innate, adaptive, and hematopoietic pathways. While individual adjuvants differentially regulate immune and platelet-associated genes, common pathway-level patterns emerge across formulations. These findings suggest candidate mechanisms for prolonged vaccine efficacy and provide actionable insights to guide rational adjuvant design for sustained immune protection.